Experiences with

Prialt

40% of phase 1 clinical trials fails because of lack of enrolled patients....this is something I did not expect.... https://www.youtube.com/watch?v=Sys9Ki6t4DQ

Next month, patients with severe, rare, and incurable diseases such as arthritis, autoimmune diseases, Parkinson's disease, and cancer will be able to receive stem cell and immune cell therapies currently in the development stage. Until now, patients in South Korea were unable to use developing cell

This seems promising, however how far will they get before they lose interest and go in another direction as they always do. Time will tell, but this looks a better option than the current drugs with side effects. Aspen Neuroscience has completed dosing the first two groups of patients in ASPIRO, an

NCT05830110 Title: patterned multi channel VIBROTACTILE stimulation for the longitudinal treatment of moderate stage Parkinson’s disease. Sponsor Synergic Medical Technologies Inc. Study coordinator: Elyria Kabasenche Telephone number 541-510-7068 Email: Elyria.kabasenche.com Location: Eugene

Researchers at UMass Amherst have developed BacID, a bacteria-based cancer therapy that uses genetically engineered, non-toxic Salmonella to target tumors and deliver therapeutic agents directly into cancer cells. The bacteria, administered intravenously, preferentially colonize tumors and release their

A novel PROTAC targeting the ERG protein is being developed to address metastatic castration-resistant prostate cancer (mCRPC). ERG gene fusions, found in up to 50% of prostate cancer cases, drive tumor progression and resistance to standard treatments. This therapy aims to degrade the ERG protein, effectively

The latest in our free quarterly webinar series on 29th January at 5.00pm GMT will discuss how multi-arm, multi-stage (MAMS) clinical trial platforms can be used to accelerate the development and progression of potential therapies for Parkinson’s. Edinburgh University’s Professor Tilo Kunath will be

NRM-823 is a novel T-cell engager designed to target a specific tumor antigen prevalent in advanced prostate cancer. Preclinical studies have demonstrated its ability to effectively redirect T cells to recognize and destroy prostate cancer cells, leading to significant tumor reduction. This innovative

Promising approach for multiple tumors (even if in its early stage). RPT04402 is a first-in-class molecular glue that selectively reactivates PP2A, a tumor suppressor enzyme crucial for regulating cell growth. By restoring PP2A activity, this therapy suppresses oncogenic pathways, offering a novel

More Stem Cell Clinical Trial news from Simon Stott, The Science of Parkinson’s: Oooh! @BlueRockTx goes Phase 3! The company plans to initiate a Phase 3 clinical trial for bemdaneprocel (its investigational cell therapy) for #Parkinsons; With RMAT designation, the "exPDite-2" study is expected to begin

From X - Recent post from Simon Stott, The Science of Parkinson’s: Busy day for cell therapies: Aspen Neuroscience @AspenNeuro announces completion of dosing in the 1st & 2nd cohorts in their "ASPIRO" Phase 1/2a trial of their autologous-derived cell therapy (ANPD001) for #Parkinsons aspenneuroscience.com

Dear All We have been asked by the National Institute of Health and Care Excellence (NICE) to make a submission as part of their assessment for Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Good Morning! Is anyone on the clinical trial drug, BGB16673? I started a month ago. I have marginal zone NHL which shares many of the same meds as CLL. Thanks, Donna

I am still not overly impressed by this drug, although I understand that it has been tested on heavily pre-treated patients with very aggressive/resistant cancers... but here it is! BMS-986365, an investigational oral drug for metastatic castration-resistant prostate cancer (mCRPC), has shown promise

In the Summer 2024 edition of the research magazine of Parkinson’s UK, I was surprised to see page 14: https://www.parkinsons.org.uk/sites/default/files/2024-08/PUK1837_Progress%20magazine_April%2024_Web%20%282%29.pdf "Clinical trial results showing potential for Symprove" "Covid-19 hugely delayed

NXP800, a novel drug developed by the Institute of Cancer Research, shows promise in treating hormone-resistant prostate cancer. By targeting heat shock proteins (HSPs), which help cancer cells survive under stress, NXP800 disrupts tumor growth and allows therapies to regain effectiveness. In preclinical

I am wondering if any of you here are on the same clinical trial at Dana Farber as I am. There is no name to the medication. I am taking 3 blue capsules in the am and another 3 at night. If you are on this, please share how. you feel on it.

Polynucleotide Kinase/Phosphatase (PNKP) is a key enzyme in DNA repair, helping cancer cells resist treatments like radiation and chemotherapy. By targeting PNKP, researchers aim to make prostate cancer cells more vulnerable to therapy-induced DNA damage. This approach is especially promising for tumors

Hello everyone, [i]This week has been a grind. [/i] My amazing future mother-in-law, who is 90 years old, has been in the hospital. Twice! Before Monday, she had not been in a hospital since her youngest son Edward (my fiance) was born—65 years ago. While she is marveling at the new technology

Hello friends, I have been following this companies exciting research as they have been developing a nano-particle platform geared at addressing the dysregulated immune system/Autoimmune disease PBC, Celiac Disease, Mystanstia Gravis etc.. Here's quote from latest news as they just received orphan